Qiao Xue, Shi Junxiu, Liu Jiayi, Liu Jinwen, Guo Yan, Zhong Ming
Department of Central laboratory, School and Hospital of Stomatology, China Medical University, Liaoning Province Key Laboratory of Oral Disease, Shenyang, China.
Department of Oral Biology, School and Hospital of Stomatology, China Medical University, Liaoning Province Key Laboratory of Oral Disease, Shenyang, China.
Front Oncol. 2021 May 19;11:647200. doi: 10.3389/fonc.2021.647200. eCollection 2021.
This study aimed to systematically investigate and compare the post-treatment recurrence of intraosseous ameloblastoma in patients treated with conservative or aggressive approaches.
Systemic searches of PubMed, Medline, Cochrane Library, and Embase databases from inception to October 28, 2020, were conducted. Studies that aimed to evaluate the recurrence of intraosseous ameloblastoma by conservative and aggressive treatment approaches were included.
A total of 20 studies with 942 ameloblastoma cases were included. Fourteen studies included patients with ameloblastoma who received conservative treatment, and 16 studies reported the overall recurrence rate for patients undergoing aggressive treatment. The pooled results indicated that the recurrence rate for aggressive treatment [0.12, 95% confidence interval (CI) = 0.09-0.16] was significantly lower than that for conservative treatment, with a recurrence rate of 0.30 (95% CI = 0.23-0.39). Similar results were obtained when stratifying the participants by the histological classification. When trying stratification analysis following the original included studies, multicystic ameloblastoma presented a much higher recurrence rate than solid and unicystic ameloblastomas.
These findings supported the hypothesis that aggressive treatment might lead to a lower recurrence rate than conservative treatment. More studies and meta-analyses following the new histological classification of ameloblastomas are needed to validate and support the findings.
本研究旨在系统调查和比较采用保守或积极治疗方法的骨内成釉细胞瘤患者治疗后的复发情况。
对PubMed、Medline、Cochrane图书馆和Embase数据库从创建到2020年10月28日进行了全面检索。纳入旨在通过保守和积极治疗方法评估骨内成釉细胞瘤复发情况的研究。
共纳入20项研究,涉及942例成釉细胞瘤病例。14项研究纳入了接受保守治疗的成釉细胞瘤患者,16项研究报告了接受积极治疗患者的总体复发率。汇总结果表明,积极治疗的复发率[0.12,95%置信区间(CI)=0.09 - 0.16]显著低于保守治疗组,保守治疗组的复发率为0.30(95%CI = 0.23 - 0.39)。按组织学分类对参与者进行分层时也获得了类似结果。在对最初纳入的研究进行分层分析时,多囊性成釉细胞瘤的复发率远高于实性和单囊性成釉细胞瘤。
这些发现支持了积极治疗可能比保守治疗导致更低复发率这一假设。需要更多遵循成釉细胞瘤新组织学分类的研究和荟萃分析来验证和支持这些发现。